Table 2.
Pharmacotherapy
| Parameter | Historical cohort (n = 273) | Intervention cohort (n = 91) | p value |
|---|---|---|---|
| Furosemide dosing | |||
| Starting dose (mg) a | 40 (20–40) | 40 (40–40) | 0.003 |
| Day one total daily dose (mg) a | 40 (40–60) | 80 (40–120) | < 0.0001 |
| Day two total daily dose (mg)a | 0 (0–40) | 80 (20–120) | < 0.0001 |
| Day three total daily dose (mg) a | 0 (0–20) | 0 (0–80) | 0.0007 |
| Total cumulative dose (mg)a | 80 (40–200) | 240 (120–420) | < 0.0001 |
| Conversion to continuous infusion b | 32 (11.7) | 8 (8.8) | 0.562 |
| First to last dose furosemide (days) a | 4.9 (1.4–12.4) | 4.8 (3.1–9.8) | 0.165 |
| Diuresis adjuncts | |||
| Metolazoneb | 15 (5.5) | 30 (32.9) | < 0.0001 |
| Chlorothiazidec | 48 (17.6) | 6 (6.6) | 0.402 |
| Acetazolamideb | 14 (5.1) | 14 (15.4) | 0.001 |
| Albuminc | 29 (10.6) | 2 (2.2) | 0.009 |
| Day one potassium supplementationa | 40 (40–60) | 60 (40–80) | 0.007 |
| Day two potassium supplementationa | 40 (40–60) | 60 (40–100) | 0.002 |
| Day three potassium supplementationa | 50 (40–80) | 70 (60–100) | 0.002 |
| Other medication exposure | |||
| Total nephrotoxin exposurea | 1 (1–2) | 1 (1–2) | 0.288 |
| Aminoglycosideb | 27 (9.9) | 8 (8.8) | 0.758 |
| Beta-lactamb | 227 (83.2) | 75 (92.4) | 0.872 |
| Intravenous antiviralb | 11 (4.0) | 12 (13.2) | 0.002 |
| ACE inhibitor and/or ARBb | 49 (17.9) | 13 (14.3) | 0.421 |
| Amphotericin Bc | 5 (1.8) | 3 (3.3) | 0.418 |
| Intravenous sulfamethoxazole-trimethoprimc | 19 (6.9) | 4 (7.7) | 0.465 |
| Intravenous vancomycinb | 153 (56.0) | 51 (56.0) | 1.000 |
| Combination vancomycin and piperacillin-tazobactamb | 88 (32.2) | 30 (32.9) | 0.897 |
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker
aWilcoxon rank sum, median (interquartile range)
bChi-square test; number (percentage)
cFisher’s exact, number (percentage)